Viemed Healthcare/$VMD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Viemed Healthcare
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
- Ticker
- $VMD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,438
- Headquarters
- Lafayette, United States
- Website
- www.viemed.com
VMD Metrics
BasicAdvanced
$358M
26.10
$0.36
1.12
-
Price and volume
Market cap
$358M
Beta
1.12
52-week high
$12.61
52-week low
$6.05
Average daily volume
278K
Financial strength
Current ratio
1.127
Quick ratio
0.896
Long term debt to equity
0.065
Total debt to equity
0.079
Interest coverage (TTM)
17.94%
Profitability
EBITDA (TTM)
55.799
Gross margin (TTM)
57.47%
Net profit margin (TTM)
4.81%
Operating margin (TTM)
8.47%
Effective tax rate (TTM)
29.05%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
8.21%
Return on equity (TTM)
10.45%
Valuation
Price to earnings (TTM)
26.101
Price to revenue (TTM)
1.196
Price to book
2.49
Price to tangible book (TTM)
4.27
Price to free cash flow (TTM)
12.336
Free cash flow yield (TTM)
8.11%
Free cash flow per share (TTM)
0.763
Growth
Revenue change (TTM)
25.21%
Earnings per share change (TTM)
6.51%
3-year revenue growth (CAGR)
24.54%
3-year earnings per share growth (CAGR)
23.75%
What the Analysts think about VMD
Analyst ratings (Buy, Hold, Sell) for Viemed Healthcare stock.
Analyst projections of the future price of Viemed Healthcare stock.
Bulls say / Bears say
Viemed delivered record Q2 revenue of $78.1 million, up 23.9% year on year, while active ventilator patients reached a company high of 12,635. PAP therapy, sleep resupply and maternal health also grew, giving the company several growth engines rather than relying solely on ventilation. (Viemed Healthcare 10-Q, HME Business)
Cash generation is improving as the business mix becomes less capital-intensive. Trailing twelve-month free cash flow reached $34.4 million, first-half capital expenditure was 8.3% of revenue, and management cut its full-year capital expenditure range to 8.5%–10.0%. (Viemed Healthcare 10-Q, Longbridge)
The balance sheet gives Viemed room to fund expansion and return capital: it had more cash than debt at the end of June, $46 million of undrawn credit facilities and an authorised share repurchase programme of up to 5% of shares. Its coverage presentation also argues that the more demanding ventilation rules can favour a scaled provider with established clinical operations. (Viemed Healthcare investor presentation, Viemed Healthcare 10-Q)
Profit growth is not keeping pace with sales. Q2 adjusted EBITDA fell 4% year on year, net income declined to $2.8 million from $3.2 million, and management reduced its full-year adjusted EBITDA guidance to $64 million–$68 million even while raising the bottom of its revenue range. (Viemed Healthcare 10-Q, Longbridge)
The new Medicare ventilation coverage determination creates extra qualification, documentation and ongoing utilisation requirements. That adds near-term administrative friction and execution risk, particularly while Viemed is still adapting its processes. (Viemed Healthcare investor presentation, Viemed Healthcare Q2 earnings call)
The newer growth lines may improve cash efficiency without improving profits at the same rate. Management acknowledged that rapid growth in sleep and maternal health is compressing EBITDA margins, while Q2 also included temporary integration costs, so future acquisitions and diversification may not deliver the expected synergies. (Viemed Healthcare Q2 earnings call, StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 28 Sept 2026.
VMD Financial Performance
Revenues and expenses
VMD Earnings Performance
Company profitability
Upcoming events
No upcoming events
VMD News
AllArticlesVideos
Funds containing VMD
AllEURGBP
Fund name | Fund size | $VMD weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.